ABBV Abbvie

Filed: 10 May 21, 5:00pm






Washington, D.C. 20549







Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): May 7, 2021



(Exact Name of Registrant as specified in its charter)


Delaware 001-35565 32-0375147
(State or other Jurisdiction
of incorporation)
 (Commission File Number) (IRS Employer
Identification No.)



1 North Waukegan Road

North Chicago, Illinois 60064-6400

(Address of principal executive offices) (Zip Code)


Registrant’s telephone number, including area code: (847) 932-7900


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which
Common Stock, $0.01 Par Value ABBV New York Stock Exchange
Chicago Stock Exchange
1.500% Senior Notes due 2023 ABBV23B New York Stock Exchange
1.375% Senior Notes due 2024 ABBV24 New York Stock Exchange
1.250% Senior Notes due 2024 ABBV24B New York Stock Exchange
0.750% Senior Notes due 2027 ABBV27 New York Stock Exchange
2.125% Senior Notes due 2028 ABBV28 New York Stock Exchange
2.625% Senior Notes due 2028 ABBV28B New York Stock Exchange
2.125% Senior Notes due 2029 ABBV29 New York Stock Exchange
1.250% Senior Notes due 2031 ABBV31 New York Stock Exchange


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨






Item 5.07Submission of Matters to a Vote of Security Holders.


AbbVie Inc. (“AbbVie”) held its Annual Meeting of Stockholders on May 7, 2021. The following is a summary of the matters voted on at that meeting.


 (1)The stockholders elected AbbVie’s Class III Directors with terms expiring in 2024, as follows:


Name For Against Broker Non-Votes
Roxanne S. Austin 1,176,814,309 40,193,567 266,940,608
Richard A. Gonzalez 1,143,418,886 73,588,990 266,940,608
Rebecca B. Roberts 1,178,818,824 38,189,052 266,940,608
Glenn F. Tilton 1,092,161,771 124,846,105 266,940,608


 (2)The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2021, as follows:


For Against Abstain  
1,443,141,768 38,474,335 2,332,381  


 (3)The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers listed in the proxy statement for the 2021 annual meeting, as follows:


For Against Abstain Broker Non-Votes
1,088,078,054 122,760,887 6,168,935 266,940,608


 (4)The stockholders approved the Amended and Restated 2013 Incentive Stock Program, as follows:


For Against Abstain Broker Non-Votes
1,151,977,015 60,300,643 4,730,218 266,940,608


 (5)The stockholders approved the Amended and Restated 2013 Employee Stock Purchase Plan for Non-U.S. Employees, as follows:


For Against Abstain Broker Non-Votes
1,179,691,622 33,184,479 4,131,775 266,940,608


 (6)The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows:


For Against Abstain Broker Non-Votes
1,200,648,034 12,015,517 4,344,325 266,940,608


 (7)The stockholders did not approve a stockholder proposal to issue a lobbying report, as follows:


For Against Abstain Broker Non-Votes
435,784,510 770,846,870 10,376,496 266,940,608


 (8)The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair, as follows:


For Against Abstain Broker Non-Votes
330,233,388 831,267,134 55,507,354 266,940,608







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date:May 10, 2021By:/s/ Laura J. Schumacher
   Laura J. Schumacher
   Vice Chairman, External Affairs, Chief Legal Officer, and Corporate Secretary


Common Stock, $0.01 Par ValueABBV